LONDON – The competitive potential of Alpharadin in treating bone metastases in patients with hormone-resistant prostate cancer was underlined in the first formal presentation of the Phase III study ...

As a pioneer of harnessing artificial intelligence (AI) to drug discovery, Insilico Medicine Inc. recently made breakaway progress to bring a generative... Blood cancer drug venetoclax could ...

OSLO, August 28 /PRNewswire-FirstCall/ --Results Further Support the Clinical Profile of This Novel Anti-Cancer Agent Under Development to Improve the Survival of ...

Tulane Cancer Center (TCC) is seeking patients to participate in a clinical trial of a new drug to treat late-stage prostate cancer. TCC is the first location in the United States to take part in this ...

Research was presented at the ASCO Genitourinary Cancers Symposium, including advancements in prostate cancer. The American Society of Clinical Oncology (ASCO) hosted the annual Genitourinary Cancers ...

After receiving a diagnosis of prostate cancer, a man will need to decide how aggressively to treat the cancer, weighing the severity of the disease against the risk of side effects. Since early ...

CHICAGO—Alpharadin, an investigational agent, may relieve pain and improve survival in men with metastatic castration-resistant prostate cancer (CRPC), according to data presented at the American ...

International prostate cancer expert Dr. Oliver Sartor of Tulane Cancer Center is the first oncologist in the United States to offer patients an experimental new treatment for late-stage prostate ...

PSA doubling time (PSADT) and proximal PSA value predict metastasis-free survival (MFS) in men with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy (RP). Neoadjuvant ...

Lindsay Curtis is a health & medical writer in South Florida. She worked as a communications professional for health nonprofits and the University of Toronto’s Faculty of Medicine and Faculty of ...